FC
MRTX

FORA Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

FORA Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,668
Closed -$203K – 673
2023
Q3 		$203K Buy
+4,668
New +$167K 0.02% 435
2022
Q4 		– Sell
-5,110
Closed -$357K – 663
2022
Q3 		$357K Buy
+5,110
New +$378K 0.07% 301
2022
Q2 		– Sell
-4,570
Closed -$380K – 735
2022
Q1 		$380K Buy
4,570
+1,808
+65% +$185K 0.07% 335
2021
Q4 		$405K Buy
+2,762
New +$429K 0.16% 178
2021
Q3 		– Sell
-1,242
Closed -$201K – 935
2021
Q2 		$201K Buy
+1,242
New +$199K 0.04% 440
2021
Q1 		– Sell
-4,347
Closed -$955K – 1187
2020
Q4 		$955K Buy
4,347
+2,475
+132% +$535K 0.15% 160
2020
Q3 		$311K Sell
1,872
-4,632
-71% -$634K 0.2% 112
2020
Q2 		$743K Buy
+6,504
New +$631K 0.25% 98
2020
Q1 		– Sell
-4,015
Closed -$517K – 1412
2019
Q4 		$517K Buy
+4,015
New +$387K 0.05% 382

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

FORA Capital's MRTX Position: Q4 2023 in Review

FORA Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 4,668 shares — an estimated $203K sold.

FORA Capital first reported a position in MRTX in Q4 2019 and held it in 9 quarters. The position peaked at $955K in Q4 2020. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • FORA Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • FORA Capital sold 4,668 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $203K.
  • FORA Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
  • FORA Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $955K in Q4 2020.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on FORA Capital's 13F filing for Q4 2023, filed 14 Feb 2024.